Skip to main content

Mean Platelet Volume: A Link Between Thrombosis and Inflammation?

Buy Article:

$68.00 + tax (Refund Policy)

Platelet activation is a link in the pathophysiology of diseases prone to thrombosis and inflammation. Numerous platelet markers, including mean platelet volume (MPV), have been investigated in connection with both thrombosis and inflammation. This review considers MPV as a prognostic and therapeutic marker as well as the factors influencing its measurement. Established cardiovascular risk factors, such as smoking, hypertension, dyslipidemia, and diabetes, can influence MPV, depending on confounding factors. Low-grade inflammation is one such factor. Evidence, particularly derived from prospective studies and a meta-analysis, suggest a correlation between an increase in MPV and the risk of thrombosis. High MPV associates with a variety of established risk factors, cardio- and cerebrovascular disorders, and low-grade inflammatory conditions prone to arterial and venous thromboses. High-grade inflammatory diseases, such as active rheumatoid arthritis or attacks of familial Mediterranean fever, present with low levels of MPV, which reverse in the course of antiinflammatory therapy. Lifestyle modification, antihypertensive, lipid-lowering and diet therapies can also affect MPV values, but these effects need to be investigated in large prospective studies with thrombotic endpoints.





Keywords: ATRA; Beta-cryptoxanthin; Blackcurrant seed oil (BCSO); Evening Primrose oil; Glucosamine sulfate; MAPKs; Megaloblastic anemia; Platelets; alpha-carotene; alphalinolenic acid; anthocyanidin resulted; apigenin; arterial thrombosis; beta-cryptoxanthin; chondroitin sulfate; collagen-induced arthritis (CIA); dihomo-linolenic; dihomo-linolenic acid; dizygotic; docosa-hexaenoic acid; eicosapentaenoic acid; epigallocatechin gallate; fibrosis; gammalinolenic; genistein; glutathione peroxidase; hy-droxytyrosol; inflammation; juvenile arthritis affects; kappaB; luteolin; lycopene; mean platelet volume; methotrexate; monozygotic; oleuropein; pannus; phosphoinositide-3-kinase; primary Sjogren's syndrome affects; prognosis; prostanoids; quercetin; rheumatic disease; spondylarthritides; synovial cell proliferation; systemic lupus erythematosus affects; systolic BP; tein/zeaxanthin; tocopherol; toll-like receptors; tumor necrosis factor al-pha; tyrosol; venous thromboembolism

Document Type: Research Article

Publication date: 01 January 2011

More about this publication?
  • Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

    Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content